Blockade of alpha 5 beta 1 integrins reverses the inhibitory effect of tenascin on chemotaxis of human monocytes and polymorphonuclear leukocytes through three-dimensional gels of extracellular matrix proteins.
Tenascin is an extracellular matrix protein found in adults in T cell-dependent areas of lymphoid tissues, sites of inflammation, and tumors. We report here that it inhibited chemotaxis of chemoattractant-stimulated human monocytes and chemoattractant-stimulated polymorphonuclear leukocytes (PMN) through three-dimensional gels composed of collagen I or Matrigel, and chemotaxis of leukotriene B4-stimulated PMN through fibrin gels. The inhibitory effect of tenascin on monocyte or PMN chemotaxis through these matrices was reversed by Abs directed against alpha5beta1 integrins or by a peptide (GRGDSP) that binds to beta1 integrins. Tenascin did not affect leukotriene B4- or fMLP-stimulated expression of beta1 or beta2 integrins, but did exert a small inhibitory effect on PMN adhesion and closeness of apposition to fibrin(ogen)-containing surfaces. Thus, alpha5beta1 integrins mediate the inhibitory effect of tenascin on monocyte and PMN chemotaxis, without promoting close apposition between these leukocytes and surfaces coated with tenascin alone or with tenascin bound to other matrix proteins. This contrasts with the role played by alpha5beta1 integrins in promoting close apposition between fMLP-stimulated PMN and fibrin containing surfaces, thereby inhibiting chemotaxis of fMLP-stimulated PMN through fibrin gels. Thus, chemoattractants and matrix proteins regulate chemotaxis of phagocytic leukocytes by at least two different mechanisms: one in which specific chemoattractants promote very tight adhesion of leukocytes to specific matrix proteins and another in which specific matrix proteins signal cessation of migration without markedly affecting strength of leukocyte adhesion.
Loike
J D
JD
Department of Physiology and Cellular Biophysics, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA. jdl5@columbia.edu
Cao
L
L
Budhu
S
S
Hoffman
S
S
Silverstein
S C
SC
D000818:Animals; D000911:Antibodies, Monoclonal / Q000502:physiology; D018821:CD18 Antigens / Q000096:biosynthesis; D002448:Cell Adhesion / Q000502:physiology; D002464:Cell Migration Inhibition; D002634:Chemotaxis, Leukocyte / Q000276:immunology / Q000502:physiology*; D002642:Chick Embryo; D003094:Collagen / Q000502:physiology*; D004338:Drug Combinations; D000939:Epitopes / Q000096:biosynthesis; D005109:Extracellular Matrix / Q000502:physiology*; D006801:Humans; D007106:Immune Sera / Q000502:physiology; D007140:Immunoglobulin Fab Fragments / Q000502:physiology; D007074:Immunoglobulin G / Q000502:physiology; D019012:Integrin beta1 / Q000096:biosynthesis; D016209:Interleukin-8 / Q000502:physiology; D007797:Laminin / Q000502:physiology*; D007975:Leukotriene B4 / Q000502:physiology; D008213:Lymphocyte Activation; D009000:Monocytes / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000276:immunology / Q000378:metabolism / Q000502:physiology*; D009842:Oligopeptides / Q000502:physiology; D011509:Proteoglycans / Q000502:physiology*; D017469:Receptors, Fibronectin / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D019063:Tenascin / Q000037:antagonists & inhibitors* / Q000276:immunology / Q000502:physiology; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology
D000911:Antibodies, Monoclonal; D018821:CD18 Antigens; D004338:Drug Combinations; D000939:Epitopes; D007106:Immune Sera; D007140:Immunoglobulin Fab Fragments; D007074:Immunoglobulin G; D019012:Integrin beta1; D016209:Interleukin-8; D007797:Laminin; D009842:Oligopeptides; D011509:Proteoglycans; D017469:Receptors, Fibronectin; D019063:Tenascin; D014409:Tumor Necrosis Factor-alpha; C059485:matrigel; D007975:Leukotriene B4; D009240:N-Formylmethionine Leucyl-Phenylalanine; C047981:arginyl-glycyl-aspartic acid; D003094:Collagen